Generic placeholder image

Current Vascular Pharmacology

Eiditor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Research Article

Galectin-3 and Arterial Stiffness in Patients with Heart Failure: A Pilot Study

Author(s): Evangelos Oikonomou, Dimitris Karlis, Sotiris Tsalamadris, Gerasimos Siasos, Christina Chrysohoou, Georgia Vogiatzi*, Stathis Dimitropoulos, Georgios Charalambous, Evangelia Kouskouni and Dimitris Tousoulis

Volume 17 , Issue 4 , 2019

Page: [396 - 400] Pages: 5

DOI: 10.2174/1570161116666180703094919

Price: $58

Abstract

Background: Cardiac performance depends on optimum ventriculoarterial coupling which is impaired in patients with heart failure (HF). Galectin-3 is a mediator of myocardial fibrosis and remodeling, and is associated with clinical status in patients with chronic HF. We examined the association of arterial stiffness with galectin-3 levels in patients with HF of ischemic etiology.

Methods: We consecutively enrolled 40 patients with stable ischemic HF and reduced ejection fraction. Central aortic stiffness was evaluated non-invasively by measuring carotid femoral pulse wave velocity (PWV). Among other factors, serum levels of galectin-3 and b-type natriuretic peptide (BNP) were measured.

Results: The median galectin-3 levels in our study population were 12.9 (10.8-18.7) ng/ml and the mean PWV was 9.31±2.79 m/sec. There was significant association of galectin-3 levels with age (r=0.48, p=0.003), creatinine clearance (r=-0.66, p<0.001) and BNP levels (r=0.36, p=0.05). There was a significant association of galectin-3 levels with PWV (r=0.37, p=0.03) and patients with PWV above median also had significantly increased levels of galectin-3 compared with patients with lower values of PWV [16.1(11.8-25.2) vs. 12.1(10.5-14) ng/ml, p=0.03].

Conclusion: We found an association of arterial stiffness and PWV with galectin-3 levels in patients with chronic HF of ischemic etiology. These findings suggest a pathway driving arterial stiffening and myocardial remodelling in HF. This may provide insight into the mechanism determining prognosis and clinical status of patients with HF.

Keywords: Arterial stiffness, galectin-3, fibrosis, heart failure, pulse wave velocity, myocardial fibrosis, B-type natriuretic peptide.

Graphical Abstract
[1]
Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.
[2]
Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404-13.
[3]
de Rivas B, Permanyer-Miralda G, Brotons C, Aznar J, Sobreviela E. Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: the INCA study. Qual Life Res 2008; 17: 1229-38.
[4]
Kass DA. Ventricular arterial stiffening: Integrating the pathophysiology. Hypertension 2005; 46: 185-93.
[5]
Chirinos JA, Sweitzer N. Ventricular-arterial coupling in chronic heart failure. Card Fail Rev 2017; 3: 12-8.
[6]
Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012; 30: 445-8.
[7]
Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European society of cardiology working group on peripheral circulation: Endorsed by the association for research into arterial structure and physiology (ARTERY) society. Atherosclerosis 2015; 241: 507-32.
[8]
Pandey A, Khan H, Newman AB, et al. Arterial stiffness and risk of overall heart failure, heart failure with preserved ejection fraction, and heart failure with reduced ejection fraction: The health abc study (health, aging, and body composition). Hypertension 2017; 69: 267-74.
[9]
O’Rourke MF, Pauca A, Jiang XJ. Pulse wave analysis. Br J Clin Pharmacol 2001; 51: 507-22.
[10]
Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013; 227: 367-72.
[11]
de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11: 811-7.
[12]
Lopez-Andres N, Rossignol P, Iraqi W, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14: 74-81.
[13]
Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
[14]
Gruson D, Mancini M, Ahn SA, Rousseau MF. Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction. Clin Chim Acta 2014; 429: 189-93.
[15]
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
[16]
Rajzer MW, Wojciechowska W, Klocek M, Palka I, Brzozowska-Kiszka M, Kawecka-Jaszcz K. Comparison of aortic pulse wave velocity measured by three techniques: Complior, SphygmoCor and Arteriograph. J Hypertens 2008; 26: 2001-7.
[17]
Bonapace S, Rossi A, Cicoira M, et al. Increased aortic pulse wave velocity as measured by echocardiography is strongly associated with poor prognosis in patients with heart failure. J Am Soc Echocardiogr 2013; 26: 714-20.
[18]
Kim DB, Baek SH, Jang SW, et al. Improvement of arterial stiffness in the transition from acute decompensated heart failure to chronic compensated heart failure. Clin Cardiol 2013; 36: 358-62.
[19]
Et-Taouil K, Safar M, Plante GE. Mechanisms and consequences of large artery rigidity. Can J Physiol Pharmacol 2003; 81: 205-11.
[20]
Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: Results from the HF-ACTION study. Circ Heart Fail 2012; 5: 72-8.
[21]
de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013; 15: 1095-101.
[22]
Edelmann F, Holzendorf V, Wachter R, et al. Galectin-3 in patients with heart failure with preserved ejection fraction: Results from the Aldo-DHF trial. Eur J Heart Fail 2015; 17: 214-23.
[23]
Di Tano G, Caretta G, De Maria R, et al. Galectin-3 predicts left ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention. Heart 2017; 103: 71-7.
[24]
Chantler PD, Lakatta EG, Najjar SS. Arterial-ventricular coupling: Mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol 2008; 105: 1342-51.
[25]
Mattace-Raso F, Hofman A, Verwoert GC, et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: Establishing normal and reference values. Eur Heart J 2010; 31: 2338-50.

Rights & Permissions Print Export Cite as
Article Metrics
24
2
1
Related Journals
Related eBooks
Related Articles
© 2019 Bentham Science Publishers